---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-022875"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:52:18.188674+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Monopar Q2 net loss $2.2M ($0.16/shr); camsirubicin at 5th dose level

## Summary
- Net loss of $2.2M ($0.16/shr) vs $2.8M ($0.22/shr) in Q2 2022.
- Cash and short-term investments $10.2M; cash runway through Sep 2024; needs more capital within 12 mos.
- Camsirubicin Phase 1b at 650 mg/m²; two patients showed 18% and 20% tumor reduction; no cardiotoxicity.
- MNPR-101 radiopharma advancing toward first-in-human studies potentially by end of 2023.
- R&D expenses decreased to $1.6M from $2.1M; G&A slightly up to $0.7M.

## SEC filing metadata
- accession: 0001437749-23-022875
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774923022875/0001437749-23-022875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774923022875/mnpr20230808_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-022875
- JSON: https://secwatch.observer/filing/0001437749-23-022875.json
- Plain text: https://secwatch.observer/filing/0001437749-23-022875.txt

## Key facts
- Earnings Releases
  Monopar Therapeutics reported second quarter ended June 30, 2023 results: net income $2.2 million or $0.16 per share, EPS $0.16 per share.
  - Period: second quarter ended June 30, 2023
  - Net income: $2.2 million or $0.16 per share
  - EPS: $0.16 per share
  - Result: reported results
  source text: Net loss for the second quarter of 2023 was $2.2 million or $0.16 per share compared to net loss of $2.8 million or $0.22 per share for the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774923022875/0001437749-23-022875-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.